:37AM Alimera Sciences announces United Kingdom Granted ILUVIEN Marketing Authorization for the treatment of chronic diabetic macular edema (ALIM) 2.79 : Co announced the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA) has granted marketing authorization for ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. Alimera licenses ILUVIEN from pSivida Corp (PSDV).
Market Data 
Markets 
